Summary： The specimens of ductal carcinoma in situ （DCIS） with early invasion, and specimens col- lected by core needle biopsy （CNB） tend to contain limited amount of invasive component, so it is im- perative to ...Summary： The specimens of ductal carcinoma in situ （DCIS） with early invasion, and specimens col- lected by core needle biopsy （CNB） tend to contain limited amount of invasive component, so it is im- perative to explore a new technique which can assess HER2 gene status accurately for the limited inva- sive cancer component in these specimens. Dual staining technique of combining immunohistochemis- try （IHC） for myoepithelial cells and single or dual probe chromogenic in situ hybridization （CISH） for HER2 gene was performed on routinely processed paraffin sections from 20 cases diagnosed as having DCIS with invasive cancer. Among them, 10 had fluorescence in situ hybridization （FISH）-confirmed amplification of HER2 and 10 had FISH-confirmed non-amplification of HER2. We successfully de- tected HER2 genetic signals and myoepithelial IHC markers （SMM-HC or CK5/6） simultaneously on a single section in all 20 specimens. Myoepithelial markers and HER2 signals detected by dual staining assay were consistent with those by individual technique performed alone. HER2 gene amplification results determined by dual staining assay were 100% consistent with those of FISH. Dual staining tech- nique which allows simultaneous detection of myoepithelial marker protein and cancerous HER2 gene is feasible, and it has potential to be used in clinical practice for effective determination of HER2 ampli- fication in limited invasive component.展开更多
基金supported by grants from the Natural Science Foundation of Hubei Province (No. 2008CDB152)Science and Technology Foundation of Hubei Province (No.2007AA402A40)
文摘Summary： The specimens of ductal carcinoma in situ （DCIS） with early invasion, and specimens col- lected by core needle biopsy （CNB） tend to contain limited amount of invasive component, so it is im- perative to explore a new technique which can assess HER2 gene status accurately for the limited inva- sive cancer component in these specimens. Dual staining technique of combining immunohistochemis- try （IHC） for myoepithelial cells and single or dual probe chromogenic in situ hybridization （CISH） for HER2 gene was performed on routinely processed paraffin sections from 20 cases diagnosed as having DCIS with invasive cancer. Among them, 10 had fluorescence in situ hybridization （FISH）-confirmed amplification of HER2 and 10 had FISH-confirmed non-amplification of HER2. We successfully de- tected HER2 genetic signals and myoepithelial IHC markers （SMM-HC or CK5/6） simultaneously on a single section in all 20 specimens. Myoepithelial markers and HER2 signals detected by dual staining assay were consistent with those by individual technique performed alone. HER2 gene amplification results determined by dual staining assay were 100% consistent with those of FISH. Dual staining tech- nique which allows simultaneous detection of myoepithelial marker protein and cancerous HER2 gene is feasible, and it has potential to be used in clinical practice for effective determination of HER2 ampli- fication in limited invasive component.
